Johnson and Johnson 2010 Annual Report Download - page 63

NOTES TO CONSOLIDATED FINANCIAL ST A TEMENTS61
18. Segments of Business(1) and Geographic Areas
Sales to Customers(2)
__________________________________________
(Dollars in Millions) 2010 2009 2008
Consumer —
United States $5,519 6,837 6,937
International 9,071 8,966 9,117
Total 14,590 15,803 16,054
Pharmaceutical —
United States 12,519 13,041 14,831
International 9,877 9,479 9,736
Total 22,396 22,520 24,567
Medical Devices and Diagnostics —
United States 11,412 11,011 10,541
International 13,189 12,563 12,585
Total 24,601 23,574 23,126
Worldwide total $61,587 61,897 63,747
Operating Profit Identifiable Assets
__________________________________________ ______ ____________________________________
(Dollars in Millions) 2010(5) 2009(6) 2008(7) 2010 2009 2008
Consumer $2,342 2,475 2,674 $23,753 24,671 23,765
Pharmaceutical 7,086 6,413 7,605 19,961 21,460 19,544
Medical Devices and Diagnostics 8,272 7,694 7,223 23,277 22,853 20,779
Total 17,700 16,582 17,502 66,991 68,984 64,088
Less: Expense not allocated to segments(3) 753 827 573
General corporate(4) 35,917 25,698 20,824
Worldwide total $16,947 15,755 16,929 $102,908 94,682 84,912
Additions to Property, Depreciation and
Plant & Equipment Amortization
__________________________________________ ______ ____________________________________
(Dollars in Millions) 2010 2009 2008 2010 2009 2008
Consumer $526 439 499 $532 513 489
Pharmaceutical 508 535 920 912 922 986
Medical Devices and Diagnostics 1,113 1,114 1,251 1,270 1,124 1,146
Segments total 2,147 2,088 2,670 2,714 2,559 2,621
General corporate 237 277 396 225 215 211
Worldwide total $2,384 2,365 3,066 $2,939 2,774 2,832
Sales to Customers(2)Long-Lived Assets(8)
______ ____________________________________ ______ ____________________________________
(Dollars in Millions) 2010 2009 2008 2010 2009 2008
United States $29,450 30,889 32,309 $23,315 22,399 21,674
Europe 15,510 15,934 16,782 16,791 17,347 14,375
Western Hemisphere excluding U.S. 5,550 5,156 5,173 3,653 3,540 3,328
Asia-Pacific, Africa11,077 9,918 9,483 2,089 1,868 1,898
Segments total 61,587 61,897 63,747 45,848 45,154 41,275
General corporate 715 790 785
Other non long-lived assets 56,345 48,738 42,852
Worldwide total $61,587 61,897 63,747 $102,908 94,682 84,912
(1)See Note 1 for a description of the segments in which the Company operates.
(2) Export sales are not significant. In 2010, 2009 and 2008, the Company did not have a customer that represented 10% of total revenues.
(3) Amounts not allocated to segments include interest (income) expense, non-controlling interests and general corporate (income) expense.
(4) General corporate includes cash and marketable securities.
(5)Includes $966 million of net litigation gain, comprised of a $333 million expense in the Pharmaceutical segment and a gain of $1,299 million in the Medical Devices and Diagnostics
segment. Includes $569 million of product liability expense, comprised of $114 million in the Pharmaceutical segment and $455 million in the Medical Devices and Diagnostics segment.
The Medical Devices and Diagnostics segment also includes $280 million expense for the cost associated with the DePuy ASR™Hip recall program.
(6) Includes $1,186 million of restructuring expense, comprised of $369 million, $496 million, and $321 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics
segments, respectively. Includes $386 million of fourth quarter net litigation gain, comprised of a $92 million expense in the Pharmaceutical segment and a gain of $478 million in the
Medical Devices and Diagnostics segment.
(7) Includes $7 million and $174 million of IPR&D for the Consumer and Medical Devices and Diagnostics segments, respectively. Includes $379 million of fourth quarter net litigation gain,
comprised of a $50 million expense in the Consumer segment and a gain of $429 million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment
also includes a $536 million gain on the divestiture of the Professional Wound Care business of Ethicon, Inc.
(8)Long-lived assets include property, plant and equipment, net for 2010, 2009 and 2008 of $14,553, $14,759 and $14,365, respectively, and intangible assets and goodwill, net for 2010,
2009 and 2008 of $32,010, $31,185 and $27,695, respectively.